> For the complete documentation index, see [llms.txt](https://www.parapathology.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.parapathology.com/systemic-pathology/gastrointestinal-pathology/colon-and-rectum/colon-colorectal-carcinoma.md).

# Colon Colorectal Carcinoma

## Molecular Pathology of Colorectal Cancer

Harada, Shuko MD; Morlote, Diana MD[Author Information ](https://journals.lww.com/anatomicpathology/Abstract/2020/01000/Molecular_Pathology_of_Colorectal_Cancer.4.aspx#)Advances In Anatomic Pathology: [January 2020 - Volume 27 - Issue 1 - p 20-26](https://journals.lww.com/anatomicpathology/toc/2020/01000)doi: 10.1097/PAP.0000000000000247

{% embed url="<https://journals.lww.com/anatomicpathology/Abstract/2020/01000/Molecular:Pathology:of:Colorectal:Cancer.4.aspx>" %}

## Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology

<https://www.ema.europa.eu/en/documents/presentation/presentation-session-5-approval-pembrolizumab-msi-h/dmmr-considerations-site-agnostic-development-drugs-oncology-steven-lemery_en.pdf>

## Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Colon and Rectum

<https://documents.cap.org/protocols/cp-gilower-colonrectum-14biomarker-1201.pdf>

## NCCN Guidelines Colon Cancer

<https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf>

## FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

<https://www.fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer>

## Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population

[Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population](https://onlinelibrary.wiley.com/doi/10.1111/his.14390/full)

Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20

<https://link.springer.com/article/10.1007/s00428-021-03260-w>